Literature DB >> 19463421

Refining the approach to renal artery revascularization.

Robert D Safian1, Ryan D Madder.   

Abstract

Renal artery stenosis (RAS) is caused by a heterogenous group of diseases with different pathophysiology, clinical manifestations, treatment approaches, and outcomes. The 2 most common forms of RAS are fibromuscular dysplasia (FMD) and atherosclerosis (ARAS). Renovascular syndromes are broadly classified into renovascular hypertension and ischemic nephropathy, but these terms are misleading, because they imply a causal relationship between RAS, hypertension, and renal dysfunction, which is difficult to prove in humans. Data supporting renal revascularization are limited by heterogeneous causes of hypertension and renal dysfunction, insufficient understanding of the relationship between RAS and nephropathy, inconsistent techniques for revascularization, ambiguous terminology and end points to assess benefit, and lack of large-scale randomized trials. The purpose of this review is to enhance understanding of the epidemiology, clinical markers, and diagnosis of RAS; the relationship between RAS and important disease states; the distinction between renal ischemia and nephropathy; optimal revascularization techniques; and avoidance of renal injury.

Entities:  

Mesh:

Year:  2009        PMID: 19463421     DOI: 10.1016/j.jcin.2008.10.014

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  17 in total

Review 1.  Renovascular hypertension: screening and modern management.

Authors:  Iris Baumgartner; Lilach O Lerman
Journal:  Eur Heart J       Date:  2011-01-27       Impact factor: 29.983

Review 2.  Timing and selection for renal revascularization in an era of negative trials: what to do?

Authors:  Stephen C Textor; Michael M McKusick; Sanjay Misra; James Glockner
Journal:  Prog Cardiovasc Dis       Date:  2009 Nov-Dec       Impact factor: 8.194

3.  Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis.

Authors:  Ahmed Saad; Sandra M S Herrmann; Alfonso Eirin; Christopher M Ferguson; James F Glockner; Haraldur Bjarnason; Michael A McKusick; Sanjay Misra; Lilach O Lerman; Stephen C Textor
Journal:  Circ Cardiovasc Interv       Date:  2017-09       Impact factor: 6.546

Review 4.  Renovascular hypertension and ischemic nephropathy.

Authors:  Stephen C Textor; Lilach Lerman
Journal:  Am J Hypertens       Date:  2010-09-23       Impact factor: 2.689

5.  Persistent kidney dysfunction in swine renal artery stenosis correlates with outer cortical microvascular remodeling.

Authors:  Alfonso Eirin; Xiang-Yang Zhu; Victor H Urbieta-Caceres; Joseph P Grande; Amir Lerman; Stephen C Textor; Lilach O Lerman
Journal:  Am J Physiol Renal Physiol       Date:  2011-03-02

6.  Renal microvascular disease determines the responses to revascularization in experimental renovascular disease.

Authors:  Alejandro R Chade; Silvia Kelsen
Journal:  Circ Cardiovasc Interv       Date:  2010-06-29       Impact factor: 6.546

7.  Endothelin-a receptor antagonism after renal angioplasty enhances renal recovery in renovascular disease.

Authors:  Alejandro R Chade; Nathan Tullos; Nicholas J Stewart; Bret Surles
Journal:  J Am Soc Nephrol       Date:  2014-11-06       Impact factor: 10.121

Review 8.  Diagnosis and therapy of atheromatous renal artery stenosis.

Authors:  Masayuki Tanemoto
Journal:  Clin Exp Nephrol       Date:  2013-03-26       Impact factor: 2.801

9.  Stent revascularization restores cortical blood flow and reverses tissue hypoxia in atherosclerotic renal artery stenosis but fails to reverse inflammatory pathways or glomerular filtration rate.

Authors:  Ahmed Saad; Sandra M S Herrmann; John Crane; James F Glockner; Michael A McKusick; Sanjay Misra; Alfonso Eirin; Behzad Ebrahimi; Lilach O Lerman; Stephen C Textor
Journal:  Circ Cardiovasc Interv       Date:  2013-07-30       Impact factor: 6.546

Review 10.  Management of atherosclerotic renovascular disease after Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL).

Authors:  Sandra M S Herrmann; Ahmed Saad; Stephen C Textor
Journal:  Nephrol Dial Transplant       Date:  2014-04-09       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.